Clinical Trials Logo
  1. Home
  2. Other
  3. NCT06314750

Deep Learning Based MRI Radiomics in Predicting the Clinical Risk of Locally Advanced Rectal Cancer

Locally Advanced Rectal Carcinoma Clinical Trial

Official title:
Deep Learning Based MRI Radiomics in Predicting the Clinical Risk of Locally Advanced Rectal Cancer

Clinical Trial Summary

Neoadjuvant therapy is the standard diagnosis and treatment strategy for locally advanced rectal cancer defined by MRI in order to achieve tumor regression, thus affecting the selection of surgical strategy and circumferential margin, improving the safety of operation and the prognosis of patients. This study focused on the related clinical factors such as tumor regression before and after neoadjuvant therapy, combined with preoperative high-dimensional features such as radiomics, to predict the related factors of tumor regression of locally advanced rectal cancer, and validate it with multicenter. In order to develop an accurate model that can be applied to the real world and stratify the risk of locally advanced rectal cancer patients before treatment.

Clinical Trial Description

The patients with locally advanced rectal cancer were collected retrospectively, and the relevant information such as clinical baseline characteristics, imaging data and preoperative/postoperative pathological data were collected and integrated, applying the method of deep learning to construct the model, in order to predict and evaluate the risk factors (invasion of mesorectal fascia, status of cancer nodule, long-term prognosis, tumor recurrence, etc.) which are important in clinical diagnosis and treatment. After the model was established, prospective studies were carried out to validate the model, continue training and enrich the effectiveness of the model. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06314750
Study type Observational
Source Sixth Affiliated Hospital, Sun Yat-sen University
Contact
Status Active, not recruiting
Phase
Start date January 1, 2010
Completion date September 30, 2027
View Details
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05920928 - Comparison of the Clinical Response of Total Neoadjuvant Treatment of Two Methods of Long-term or Short-term Chemoradiotherapy in Rectal Cancer N/A
Completed NCT06314737 - Assessment of Efficacy of Neoadjuvant Therapy in Locally Advanced Rectal Cancer
Recruiting NCT05524012 - Longitudinal Multimodal Response Assessment During Neoadjuvant Treatment of Rectal Cancer
Recruiting NCT05601505 - Circulating Tumor DNA-guided Neoadjuvant Treatment Strategy for Locally Advanced Rectal Cancer Phase 2
Recruiting NCT05876026 - MRI T1 Relaxation Time in Rectal Cancer
Completed NCT05622357 - Prospective Study of Short Course Radiation Therapy Followed by Neoadjuvant Chemotherapy and Surgery in Locally Advanced Rectal Cancer Phase 2
Terminated NCT04406857 - Testing the Addition of a Radiation Sensitizing Drug, IPdR, to the Usual Chemotherapy Treatment (Capecitabine) During Radiation Therapy for Rectal Cancer Phase 1
Not yet recruiting NCT06292975 - Exercise for Improving Radiotherapy Efficacy in Rectal Cancer N/A
Not yet recruiting NCT06276686 - Exercise for Improving Long-course Chemoradiotherapy Efficacy in People With Locally Advanced Rectal Cancer N/A
Recruiting NCT05591534 - Endorectal Brachytherapy for Rectal Cancer Phase 2
Recruiting NCT05722288 - Time-Restricted Eating Versus Nutritional Counseling for the Reduction of Radiation or Chemoradiation Tx Side Effects in Patients With Prostate, Cervical, or Rectal Cancers Phase 2
Not yet recruiting NCT05645094 - Neoadjuvant Envafolimab in Resectable and Locally Advanced MSI-H/dMMR Rectal Cancer
Recruiting NCT05731726 - Serplulimab Combined With CAPEOX + Celecoxib as Neoadjuvant Treatment for Locally Advanced Rectal Cancer Phase 2
Recruiting NCT06312982 - A Series of Neoadjuvant Chemoradiotherapy Combined With Immunotherapy for Locally Advanced Rectal Cancer: From a Multicenter Phase II Cohort to a Phase III Randomized Controlled Study Phase 2/Phase 3
Recruiting NCT04703101 - Short Course Radiation Therapy and Combination Chemotherapy for the Treatment of Stage II-III Rectal Cancer Phase 1
Recruiting NCT05610163 - Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation Phase 2
Recruiting NCT05245786 - An Investigational Scan (64Cu-Labeled M5A Antibody) in Combination With SOC Chemotherapy and Radiotherapy in Locally Advanced Rectal Cancer Early Phase 1
Terminated NCT03280277 - Ferumoxytol-Enhanced MRI in Imaging Lymph Nodes in Patients With Locally Advanced Rectal Cancer Early Phase 1
Recruiting NCT05772923 - Organ Preservation in Rectal Cancer: Contact X-ray Brachytherapy vs Extending the Waiting Interval and Local Excision N/A
Recruiting NCT05792735 - Neoadjuvant Cadonilimab Plus Chemotherapy Following Short-Course Radiotherapy in Locally Advanced Rectal Cancer Phase 2